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ABSTRACT
Aim: Although many patients with anxiety and depression suffer from muscular pain and bodily dys-
functions, body is largely ignored in treatment. The aim of this study was to investigate the effective-
ness of Learning Oriented Physiotherapy (LOP), based on recent knowledge about overlapping brain
networks and the need of awakening body awareness in order to synchronise body and mind.
Methods: Patients with moderate anxiety and/or depression referred to three outpatient psychiatric
clinics in Norway during October 2014 to January 2016 were invited to participate. Of eligible patients,
42 were randomised to LOP and 39 to standard psychiatric treatment (controls). Self-reports of anxiety
and depression (HADS), health-related quality of life (EQ-5D-5L) and global health (EQ-VAS) were
recorded every 6 months from baseline (T1) to 18 months after (T4). Mixed linear model (MLM) ana-
lysis was used to estimate overall differences between groups.
Results: After 1 year of follow-up, LOP participants reported higher quality of life and perceived global
health than controls. At the end of the trial, there were no mean differences in health outcomes
between groups, but LOP participants showed an overall faster rate of recovery than controls.
Conclusions: LOP may be as effective as conventional therapies for patients with moderate anxiety
and depression.
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Musculoskeletal and mental health disorders are two condi-
tions resulting in some of the highest burdens in terms of
disability and health [1–3]. These disorders are commonly
associated with reduced quality of life, with negative conse-
quences for third parts like partners and families [4].
Globally, it has been estimated that one in three or four per-
sons will be affected by anxiety, depression or another com-
mon mental disorder in the course of their life [5]. The
comorbidity between anxiety and depression is high [6,7], as
well as it is between mental disorders and somatic symp-
toms [8,9]. Today, the most common forms of treatment for
(moderate) anxiety and depression are different forms of psy-
chotherapy in combination with pharmacological treatment.
However, it is estimated that 40% of patients do not seek
treatment [7]. Although patients with anxiety and depression
largely experience improvement following psychiatric treat-
ment, relapses are frequent (25–60%) and long term effects
remain largely unclear [10,11].
Despite that physical activity and lifestyle interventions com-
monly are recommended for patients with mental disorders
[12,13], bodily dysfunctions are largely ignored, not only in the
diagnostic and treatment recommendations [14], but also in
research. In fact, many patients report symptoms such as tight-
ness in the chest, pain, stiffness, dizziness, numbness, palpita-
tions, breathlessness, exhaustion, sleep disorders or a feeling of
detachment from their own body [15,16]. A range of comple-
mentary (body mind) treatments are offered [17], but their
effectiveness are largely unclear, especially with respect to
relapses and long-term effects. High-quality trials have been
requested, with longer follow-up time and larger sample sizes,
assessing sensitive, validated outcome measures [18]. In this
study, therefore, we have investigated the effect of a clinically
derived and developed physical therapy intervention named
Learning Oriented Physiotherapy (LOP).
LOP has its origin in psycho-motoric physiotherapy, but
has been inspired by recent neuroscientific evidence of dis-
tributed neural networks as the mechanistic basis of human
behaviour and mental life [19–22]. The dynamic interaction
CONTACT Grete Bratberg grete.bratberg@nord.no Faculty of Nursing and Health Sciences, Nord University, Røstad, Levanger, 7601, Norway
 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.
0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in
any way.
EUROPEAN JOURNAL OF PHYSIOTHERAPY
https://doi.org/10.1080/21679169.2020.1739747
of functionally, specialised brain networks may help explain
the emergence of many psychiatric symptoms [21,23–25].
Also, the observed close association of bodily and mental
symptoms may be understood in terms of network interac-
tions [16,26]. Disorganisation of neural circuits may underly
disturbance of normal cognitive, emotional and self-reflective
functions, as well as body awareness and ownership [19].
Patients with anxiety and depression may suffer from a range
of bodily ailments, but according to amounts of clinical
experience, imbalance or dizziness are considered key fea-
tures shared by most patients.
In order to handle imbalance, many patients compensate
with increased tension in antigravity muscles and with the use
of their vision fixed on external objects [27,28]. Since vision is
primarily meant for navigation, it is considered less suitable as
sense organ for updating balance. LOP as therapeutic inter-
vention intends to activate and restore patients’ basic balance
system, i.e. proprioceptive information and the vestibular sys-
tem, but also to unlearn compensatory and inexpedient use
of vision. The balance and the use of vision are, therefore,
given the main focus of attention in LOP.
In contrast to most mental therapy forms, the patients are
invited to and committed as collaborating partners in an
active learning process, coached by the physiotherapist.
Patients learn how to focus and practise a set of movement
patterns integrated into daily life activities (https://www.bal-
ansekoden.no/). The simplicity of these activities aims to
motivate and easily increase the patients’ sense of achieve-
ment [29].
The results of a pilot study (not published) where LOP was
tested on 34 selected patients, suggested that symptoms of
anxiety, depression and bodily sensations of discomfort
declined during 2 years of follow-up and that patients reported
improvements in health-related quality of life and functioning
with no observed side-effects. Since the pilot study was without
controls, we wanted to conduct a pragmatic RCT with the pri-
mary aim to investigate the effectiveness of LOP on outpatients
diagnosed with moderate symptoms of anxiety and/or depres-
sion, both in a shorter and longer term perspective.
Secondarily, we wanted to examine the overall effectiveness of
LOP on health-related quality of life and perceived glo-
bal health.
Assessed for eligibility (n=370) 
Excluded  (n=289) 
♦ Not meeting diagn. inclusion criteria (n=170) 
♦ Declined to participate or other reasons (n=119) 
Analysed  (n=28 ) 
Lost to follow-up between T1 and T2 (reported 
LOP did not work for them) (n=5)  
Allocated to intervention (n= 42 ) 
♦ Received allocated intervention (n=33  )
♦ Did not receive allocated intervention 
(unknown reasons) (n=4 )
Lost to follow-up between T1 and T2, unknown 
reasons (n=6) 
Lost to follow-up between T2 and T3  of 
unknown reasons) (n=3)
Allocated to intervention (n=39  ) 
♦ Received allocated intervention (n=35  )
♦ Did not receive allocated intervention 
(unknown reasons) (n=4 )






Figure 1. Flowchart showing participation and drop out in treatment groups.
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Materials and methods
Trial design
The study was a pragmatic RCT comparing health-related
outcomes in patients that received LOP with patients who
received standard psychiatric treatment (available psycho-
therapies). Participants were followed 18 months (Figure 1)
with four data assessments. The order of the following sec-
tion follows the Consort statement [30,31].
Participants
Participants were recruited continuously during the period
October 2014 to February 2016 at three public psychiatric
clinics geographically located in different parts of Norway. Of
423 patients referred from their general practitioners for
symptoms of anxiety and depression, 370 patients met the
inclusion criteria of being 18 years of age or older, literate in
Norwegian and able to give their consent voluntarily. A total
of 170 patients did not meet the diagnostic criteria, leaving
200 eligible for participation. The diagnoses (Table 1) were
confirmed by a psychologist or a psychiatrist at each clinic.
Of the 200 patients who were invited, 81 consented to par-
ticipate in the study. A majority of those who declined to
participate (exact number unknown) wanted to receive
standard psychotherapy (or treatment as usual). Four
patients with anxiety and/or mild or moderate depression as
a secondary psychiatric diagnosis were included in the study.
Of the 81 patients allocated for participation, the distribution
of participants at the three hospital clinics was 36 (44%), 35
(44%) and 10 (12%), respectively.
The collected data were mainly obtained from self-
reported questionnaires, but information about age, diagno-
sis and relevant medication was obtained from electronic
hospital health records. Administrative staff members at each
of the hospitals were responsible for the distribution and col-
lection of all questionnaires during the project period. The
participants completed the questionnaires before the first
treatment (T1, N¼ 81), 6 months after the start of treatment
(T2, N¼ 62), 12 months after the start of treatment (T3,
N¼ 56) and 18 months after the start of treatment
(T4, N¼ 52).
If the outpatient treatment was completed, the question-
naires were sent to the participants’ home address, with a
prepaid envelope in which to return the completed form. To
motivate their response, each participant was informed they
would receive two lottery scratch cards upon submission of
their questionnaires. A first written reminder was sent from
each of the local hospitals after 2–3 weeks. A second
reminder was conducted by telephone to motivate participa-
tion and to clarify the reasons for missing responses. All tele-
phone contacts were made by one responsible and qualified
project assistant at one of the hospitals. One of the three
physiotherapists coordinated the work between the hospitals
and was responsible for processing, quality assurance and
preparation of the data for analysis.
Interventions
LOP as intervention
The intervention was offered by three LOP-authorised and
experienced physiotherapists (one at each of the three clin-
ical settings) in their usual clinical settings. In the first weeks
of treatment, patients met once a week (60min). After that,
the frequency of consultations varied to some extent
depending on patient’s individual needs.
In LOF, the learning aspect is central and the patients are
invited to start a learning process that largely intends to be
patient-driven. The first meeting, therefore, aims to evaluate
the patients’ ability to make changes on their own and the
need of support from the therapist. The therapist explains
the theoretical basis of LOP and what the treatment involves.
Line drawings are used to facilitate the dissemination of
information.
A test on an ordinary balance pad enables the patient to
become aware of his or her own bodily function/dysfunction,
but also the use of their vision as a compensatory mechan-
ism to handle dizziness. Therefore, it is of particular interest
for the therapist to observe, and for the patient to experi-
ence, how much balance depends on the use of vision.
Change of movement patterns requires, of course, unlearning
of habitual movements and learning of new ones.
Utilisation of everyday actions as therapeutic tools. All
sense organs providing information about the position and
movements of the body may contribute to the maintenance
Table 1. Baseline characteristics of participants (N¼ 81).
Characteristics N All, Mean (SD) LOP, n¼ 42, Mean (SD) Controls, n¼ 39, Mean (SD) p Value
Age, years 81 32.7 (11.6) 33.7 (12.4) 31.7 (10.7) .40
Years of symptoms 81 6.6 (7.1) 5.8 (4.7) 7.5 (9.0) .30
– – % (n) % % –
Gender Women 60 (50) 60 64 .67
– Men 40 (31) 40 36 –
Education Highera 23 (19) 33 13 .02
Medicationb Yes 36 (27) 38 33 .60
Employment Yes 60 (49) 64 56 .47
Disability pension No 96 (78) 100 92 .07
Diagnosesc 1. Anxiety 53 (42) 48 59 .14
– 2. Depression 38 (32) 48 28 –
– 3. Otherþ/AD 9 (7) 5 13 –
aUniversity/college versus lower.
bOf relevance for mental health condition.
cDiagnosis codes: 1¼ F40.0–F43.9; 2¼ F32.0, F32.1, F33.0, F33.1, F34.1; 3¼ F60.6, F90.0, F31.8.
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of balance [19]. Together with the vestibular apparatus, pro-
prioceptors play a dominant role, but within this group of
patients, proprioceptive information commonly seems to be
more or less neglected or not integrated with other senses
(unconsciously), observed by patients’ imbalance and lack of
bodily awareness (e.g. not able to describe the position of
their hands without seeing them). In order to reintegrate a
more beneficial use of the basic balance system, ten move-
ment sequences have been developed and constitute the
therapeutic ‘tools’ in LOP. These are daily life meaningful
movements such as e.g. rising to walk, sitting down, walking
up and down stairs, getting dressed or undressed, picking up
things from the floor – all claiming that patients need to pay
full attention to their own bodily balance during the perform-
ance. These are directed to the patients in a way characterised
by rhythm and flow, and supported by self-commands.
Simultaneously, the patients are encouraged to be aware of
how the ‘shift of attention’ towards these movement patterns
affects them and their symptoms, i.e. the sense of control and
the ability to master former challenging situations [29]. Video
records of the movements accompanied with explanatory text
(only in Norwegian) can be viewed at https://www.balanseko-
den.no/video-1.html#services.
The idea behind the method is that by utilising these
movements systematically, the patient can either prevent
loss of mental control or regain control if discomfort occurs.
Motivation to learn and practice is, of course, crucial for
achieving the expected effect of treatment.
Standard psychiatric treatment as intervention (treatment
as usual)
Participants were assigned to different clinicians at each of
the three psychiatric outpatient clinics; including psycholo-
gists, psychiatrists, psychiatric nurses, milieu therapists and
social working clinicians. Participants in the control group
received different types of counselling therapy, sometimes in
combination with pharmacological treatment. The therapists
used cognitive and/or metacognitive therapy, psychodynamic
therapy, support therapy or combinations of these
approaches, according to the patients’ needs (not recorded).
Outcomes
Symptoms of anxiety and depression and was the primary
outcome in this study. Health-related quality of life and per-
ceived global health were included as secondary outcomes.
Furthermore, the interactions between follow-up time and
treatment were included for all outcomes and are also con-
sidered to be secondary outcomes.
In addition, the participants were asked to record back-
ground information, including how long (number of years)
they had had the symptoms for which they had been
referred, their education level (primary and secondary school,
and upper secondary school or equivalent, and college and/
or university), whether they were in paid employment and if
so, how much they worked (full-time or part-time), whether
they were students (if so, on a full-time or part-time basis),
and whether they received any of the following benefits
from the public labour and welfare administration: sickness
benefits, unemployment benefits, disability pension and/or a
retirement pension.
The Hospital Anxiety and Depression scale (HADS) is a
self-reported instrument that records the degrees of anxiety
and depression [32]. HADS total consists of 14 items sepa-
rated into subscales, one for anxiety and one for depression
with respectively seven items each, and the severity of symp-
toms may be calculated both as separate anxiety or depres-
sion scores or also as sum-score. A partial scale value of 8
is commonly used as cut off for further diagnostic evaluation
of anxiety and/or depression [33]. The psychometric qualities
HADS based on Norwegian participants (including 9 general
population studies and 19 clinical trials) have shown good
internal consistency with Chronbach’s alpha ranging from
0.84 (lowest) to 0.91 (highest) [34]. HADS has shown to work
well as an instrument to assess the severity of symptoms of
anxiety and depression both in observational and clinical
studies [33,34].
EuroQol-5 Dimensions, 5 Levels (EQ-5D-5L) is used to pro-
vide a standardised, non-disease-specific measure of generic
health or health-related quality of life and developed by the
EuroQol Group (established in 1987) and introduced in 2009
(https://euroqol.org/). The measurement instrument is recom-
mended by The National Institute for Health and Care
Excellence (NICE) and is one of the most widely used instru-
ments internationally, both in clinical studies and in observa-
tion studies [35]. It has been found to have satisfactory
psychometric measurement characteristics [36–39]. Validation
studies have shown that the use of EQ-5D for assessment of
cost-effectiveness in mental health care has shown to be
more reliable for patients with more moderate symptoms
than for those with more severe and complex diagno-
ses [40].
The EQ-5D-5L index comprises five domains (dimensions),
each of which has five answer options (levels), ranging from
1 – no problem, 2 – a slight problem, 3 – a moderate prob-
lem, 4 – a severe problem, to 5, which indicates the worst
function. The five domains are mobility, self-care, usual activ-
ities, pain/discomfort and anxiety/depression. The patients
are also asked whether they perceive their health as good or
bad ‘today’ (EQ-VAS) by rating health status on a scale from
1 to 100, where 100 is the very best health status. Subscores
for each of the five domains, total sum scores, or index
scores can be calculated, as well as a separate score for glo-
bal health, measured on the EQ-VAS scale.
There are no exact limit values to indicate what can be
interpreted as a clinically significant improvement, but
machine-calculated, country-specific estimates of a minimally
important difference (MID) that might be useful in interpret-
ing changes using EQ-5D-5L were used. In our study, there-
fore, the scores of the five domains were converted into a
weighted index score (EQ index) based on studies conducted
in the UK [36] since similar weighting did not exist for the
Norwegian population. MID was estimated to be
0.037–0.069. According to a Norwegian method study in
which a health-economic evaluation of physiotherapy treat-
ment in the primary health service was performed, it was
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concluded that the EQ-5D-5L had good responsiveness (i.e.
ability to capture change over time) [39]. However, the
changes will always depend on the treatment and/or health
issues being treated [36,41].
Sample size
The required sample size, assuming a significance level of
5% and power of 80%, was calculated in advance of the trial,
claiming that with HADS as the primary outcome a sample
size of 34 in each study group was needed to demonstrate a
moderate difference in HADS total score between the two
groups, defined as a standardised effect size of 0.5. To take
into account an expected 15% loss to follow-up, all patients
who met the inclusion criteria and eligible for participation
were included.
Randomisation
Of the 81 participants included, 42 were randomised to LOP
and 39 to the control group. Randomisation was done by
the use of customised computer software from the Unit for
Applied Clinical Research (AKF) at the Norwegian University
of Technology and Science, NTNU (https://www.ntnu.edu/
mh/akf/forskning), administered by trained clerical personal
at each of the three psychiatric clinics.
Blinding
The study was single-blinded. Due to the nature of the inter-
ventions, it was not possible to blind participants or thera-
pists. Researchers responsible for data analyses and statistics
were blinded.
Statistics
Analyses were performed using IBM SPSS version 24 (IBM
SPSS Statistics, Armonk, NY) and Stata, StataCorp. 2017 (Stata
Statistical Software: Release 15. StataCorp LLC, College
Station, TX). The significance level was set at 0.05.
Differences in baseline characteristics between the LOP
group and controls were tested by using Independent sam-
ples t-tests (means) and Pearson’s chi-square tests (propor-
tions) (Table 1). Mean differences in HADS scores, the
weighted index score of EQ-5D-5L (EQ-5D index) and (EQ-
VAS) between the two groups at each target time (T1–T4)
were tested using Independent sample t-tests (Table 2).
Figure 2 shows the average scores with 95% confidence
intervals (95% CI) for each group and health outcome. In
order to investigate whether any of the interventions were
more effective than the other, mixed linear model (MLM)
analysis was performed. MLM analysis is based on all
repeated observations, taking the dependency between the
data collected for individuals into account and provides the
flexibility of modelling not only the means of the data but
their variances and covariances as well. Additionally, inter-
action effects between treatment and time were analysed
using the same models, combined with the standard likeli-
hood ratio (LR) tests.
Results
Participants flow
Figure 1 shows the participation and the dropout of study
participants from allocation (T1) to the end of the trial
18 months later (T4). After allocation, but prior to the initi-
ation of treatment, four participants from the LOP group and
4 from the control group were lost to follow-up for unknown
reasons. Between T1 and T2, six controls dropped out with-
out known reason. Five LOP participants who left early in
their course of treatment (between T1 and T2), indicated
that LOP did not work for them (Figure 1). A total of 52/81
allocated participants were followed in 18 months with four
repeated self-report assessments, including 28/42 in the LOP
group and 24/39 in the control group.
According to a dropout analysis, participants with lower
education (p¼ .05) and shorter disease symptom period
(<1 year) (p¼ .04) had a slightly higher dropout rate.
Otherwise, there were no statistical significant drop out
group differences with regard to gender (p¼ .198), age
(p¼ .076), diagnoses (p¼ .243), or other characteristics
(Table 1). The participants received an average of 14.5 h and
13.8 h of treatment in the LOP and control groups respect-
ively (p¼ .82). Registered time from the start-up to end of
treatment was on average 9 months for participants in the
LOP group and 7 months for those in the control group
(p¼ .11). In the study protocol for the trial, the maximum
treatment time period set for LOP participants was 1 year.
For nine participants, however, the time frame was slightly
extended (mean¼ 15 months). No time limit for treatment
time was set for participants in the control group, but four
patients received treatment for more than a year.
Table 2. Mean scores and mean differencesa in anxiety and depression (HADS), health-related quality of life (EQ-5D index), and global health (EQ-5D VAS)
between the LOP group and control group during follow-ups (T1–T4).
Outcome
















n¼ 24 p Value
HADS Total 19.2 18.4 .59 13.7 16.1 .23 13.1 14.9 .38 13.2 13.1 .96
Anxiety 10.9 10.4 .58 8.0 9.3 .19 7.5 8.6 .29 7.5 7.9 .71
Depression 8.4 8.0 .69 5.8 6.7 .38 5.6 6.3 .59 5.7 5.3 .69
EQ-5D-5L Index valueb 0.62 0.63 .79 0.76 0.67 .06 0.78 0.65 .02 0.76 0.74 .70
Global health 1–100 50.5 53.8 .46 62.4 57.3 .30 66.9 56.8 .05 67.4 65.2 .65
aIndependent sample t-tests, p values <.05 statistically significant differences between the groups.
bScores based on the English EQ-5D index.
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Characteristics of the participants at baseline
The participants included were in the age range 18–61 years
(mean¼ 32 years). More women (n¼ 50) than men (n¼ 31)
participated. On average, the participants have had the men-
tal disorder symptoms in 6.6 years, 25% had had them for
10 years or more and 12% for less than 1 year. A total of
60% of the participants indicated that they were in employ-
ment at the start of the study.
Primary outcome, anxiety and depression
Figure 2 shows the mean total score (95% CI) for HADS (pri-
mary outcome) for patients in both the LOP and control
group at 6, 12 and 18 months of follow-up. In both groups,
the greatest health improvements (steepest curves) were
observed the first 6 months of follow-up (not in table). While
half or more had a HADS total score of 19 or more at base-
line, this proportion was halved by the end of the trial, and
the mean HADS score was 5.6 lower than at baseline. The
unadjusted mean summarised or separate HADS scores did
not differ between the two groups at any T1–T4 assessment
(Table 2).
Secondary outcomes, health related quality of life and
global health
Figure 2 also shows the unadjusted mean total scores (95%
CI) for the EQ-5D index and EQ VAS for patients in both the
LOP and control group during follow-up. At 12 months of
follow-up (T2), LOP participants reported higher quality of
life (p¼ .02) and also higher global health (p¼ .05) than con-
trols did.
Overall treatment effects, primary and second-
ary outcomes
Multivariable adjusted analyses that included all repeated
observations from T1 to T4, showed no statistically significant
mean differences in treatment effects on mental health or
quality of life between participants in the LOP group and the
control group (Table 3). However, both for HADS (p<.001)
and for EQ-5D index (p<.001) there was a statistically signifi-
cant interaction effect between therapy and follow-up time
at T2 and T3, suggesting that LOP patients experienced a
slightly faster rate of recovery than controls did during fol-
low-up (Table 3). The interaction term between follow-up
time and perceived global health was statistically significant
at T3 (p¼ .013), but not at T2.
Discussion
After 18 months of follow up, there were no mean differen-
ces in health outcomes, suggesting that LOP was as effective
as a standard psychiatric treatment for patients included in
this study. However, overall findings suggest that LOP partici-
pants experienced a slightly faster rate of recovery during
follow-up than controls did.
All participants included in this study had initially a HADS
score of 8 or higher, which according to literature indicates a
need for referral [33]. Results suggest that mental health
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Figure 2. Self-report mean scores (95% CIs) of anxiety and depression (HADS), health-related quality of life (EQ-5D index) and global health (EQ-5D VAS) from
baseline to end of the trial, by treatment groups.
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that participants in both groups were recovering. At
6 months of follow-up, no statistically significant differences
in health outcomes between the two groups were observed,
but after 1 year, LOP participants were slightly more satisfied
with their quality of life and rated their global health higher
than the controls did. The clinical significance of this finding
is unclear, but according to the literature, the difference in
health-related quality of life is well above what is considered
a MID [41]. At the end of the study, there were no such
mean differences between respondents in the two treat-
ment groups.
According to this study, the greatest health improvements
in both groups were observed during the first 6 months, but
overall results suggest that on average, the time it took to
improve health to a certain level was shorter for LOP
patients than for controls. Although we found no mean dif-
ferences in for example symptoms of anxiety and depression
at any time point, the multivariable mixed method analyses
revealed that there was an interaction between treatment
and time, suggesting that on average, the HADS score
decreased faster in LOP participants than in controls. To our
knowledge, the temporal aspect of psychiatric rehabilitation
has received little focus in research, but faster rates of recov-
ery should be considered an advantage not only for the
patient, but also in a cost benefit perspective. The finding
underscores the advantage of using more advanced statis-
tical modelling [42], in particular, in studies with smaller sam-
ples and with many repeated observations. The size and
meaning of this finding for clinical practice are, of course,
unclear, but the temporal aspect is interesting and thus an
object for further investigation.
In spite of the well-known comorbidity between balance
and anxiety disorders in adults [43,44] as well as in children
[45,46], psychological interventions hardly ever address
patients’ balance difficulties. In LOP, the balance is given the
main focus of attention, but the therapeutic approach is
multifaceted (e.g. thinking, process, therapeutic tools, etc.)
and perhaps more composite than ‘standard psychiatric
treatment’. All elements included in LOP may be of relevance
for the observed effect and also interact, but it is not pos-
sible to disentangle the effect of one element from the
other. In other words, it is unclear to what extent the focus
on e.g. balance, vision or any of the other features explain
the progress patients made during follow-up. Although pos-
sible effect mechanisms of LOP remain unclear, findings from
this clinical trial largely support the idea that bodily balance
and mental control affect each other mutually [19,47].
Presumably, clinical improvement is correlated with altera-
tions in the structure and function of neural net-
works [21,23,24].
Studies have shown that disorganisation of neural net-
works may disturb normal cognitive, emotional and self-
reflective functions, including the sense of body awareness
and body ownership [15,16,48]. In LOP, body awareness is
considered a prerequisite for improving mental balance and
control and in that case, visual awareness may play an
important role [27,28]. Years of clinical experience have
shown that patients commonly are using their vision as a
compensatory mechanism to handle dizziness and imbal-
ance, and in order to improve body awareness, LOP patients
have to undergo a learning process claiming both unlearning
and relearning of use of their vision. Recent research sup-
ports the significance of vision in the interplay between
mental and bodily imbalance. According to van der Hoort
et al. [49], the sense of body ownership also promotes vis-
ual awareness.
Since the turn of the century, different body awareness
therapies have emerged [50]. These typically aim to normal-
ise posture, balance, breathing and muscular tension.
Although body awareness is central in LOP, the thinking
underlying LOP, as well as the therapeutic tools, are quite
different from other body awareness therapies, making it
both inappropriate and difficult to compare results across
studies. Nevertheless, in a previous 3 months follow-up body
awareness therapy study based on a very similar sample as
in LOP, interventions improved body awareness, self-efficacy,
sleep and physical coping resources more than treatment as
usual [51]. Despite the dissimilarities between studies, the
focus and efforts to increase body awareness within this
group of patients seem very appropriate. In a more recent
12 months RCT study, patients that received basic body
awareness therapy (BBAT) reported higher body awareness,
body attitude, fewer symptoms and improved self-efficacy
after 6 months after treatment termination than the controls
did. In addition, the BBAT group reported less use of other
Table 3. Adjusteda overall differencesb in treatment effects between LOP participants and controls (reference group), including HADS score, EQ index score and
EQ 5 D VAS score analysed by the use of Mixed Linear Models (N¼ 249 observations).
Model Categories
HAD score EQ index score Global health score
Adjusted 95% CI p Value Adjusted 95% CI p Value Adjusted 95% CI p Value
Constant – 18.68 13.74; 23.61 <.001 0.66 0.54; 0.78 <.001 52.66 40.93; 64.38 <.001
Treatment Controls Ref – – Ref – – Ref – –
LOP 1.19 1.87; 4.24 .445 .03 0.11, 0.05 .527 4.54 12.50; 3.42 .263
Time T1, baseline Ref – – Ref – – Ref – –
T2, 6 months 2.46 4.62; 0.30 .025 .05 0.02; 0.11 .157 3.74 3.25; 10.73 .298
T3, 12 months 3.27 5.49; 1.06 .004 .031 0.04; 0.10 .369 3.30 3.86; 10.46 .366
T4, 18 months 4.56 6.87; 2.25 .000 .115 0.04; 0.19 .001 10.61 3.15; 18.07 .005
Time treatment T1/Controls Ref – – Ref – – Ref – –
T2 3.08 6.06; 0.09 .043 0.09 0.00; 0.18 .048 7.88 1.78; 17.54 .110
T3 3.35 6.45; 0.25 .034 0.14 0.04; 0.23 .005 12.70 2.68; 22.71 .013
T4 1.62 4.78; 1.54 .316 0.02 0.07; 0.12 .649 6.02 4.21; 16.25 .249
aAdjusted for age, gender and education.
bDifferences estimated and reported as marginal mean regression coefficients (95% CIs).
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health and social services 1 year after baseline. In this study,
however, BBAT was only used complementary [52].
Contrary to most physiotherapies, LOP is not complemen-
tary, but used instead of conventional psychiatric medicine
and thus an alternative treatment approach. Unfortunately,
there is a lack of high-quality evidence of the effect of both
conventional and complementary therapeutic interventions
on anxiety and depression, and in particular in patients that
suffer from both mental and musculoskeletal disorders.
According to a recent scoping review [18], only one out of
111 systematic reviews on the effect of complementary
medicine (mind-body therapies) on musculoskeletal and
mental disorders, investigated the comorbidity between
these disorders. Partly, this may be due to the costs by con-
ducting high-quality clinical trials, but also the complexity of
questions and mechanisms that need to be handled. For
example, a recent meta-analysis of RCT’s on exercise con-
cluded that exercise was an effective intervention for uni-
polar depression when given independently, but not in
comparison with psychological treatments and antidepres-
sant medication [53]. Future research, therefore, ought to
investigate both independent and combined effects of inter-
ventions that aim to improve health in patients with comor-
bid mental and bodily dysfunctions.
Psychological therapies such as cognitive behaviour ther-
apy and antidepressants have proven benefit for treating
both depression and anxiety, but relapses are common and
many patients do not seek psychiatric treatment [7,54].
Accordingly, there has been increasing interest and use of
complementary and alternative medicine (CAM), such as
mind-body or lifestyle interventions [55,56]. Findings have
shown that CAM may appear as more attractive than con-
ventional psychiatric therapies to many patients. One explan-
ation is that such therapies are more congruent with users’
own values, beliefs and philosophical orientations towards
health and life [57]. On the other hand, not seeking psychi-
atric treatment is not necessarily a result of being dissatisfied
or not trusting conventional medicine [57,58]. Studies have
shown that an overwhelming majority of patients using CAM
approaches do so to complement conventional care rather
than as an alternative to conventional care [55]. It is not clear
from this clinical trial though, if the effect could have been
even more pronounced if LOP was combined with conven-
tional therapies. In fact, some of the patients in both treat-
ment arms were medicated, but the possible adjunctive
effect of medication within or between the groups is unclear
(no differences in use between groups at baseline).
Although the mechanisms underlying the symptoms
ought to be found in the brain, LOP as a therapeutic
approach is a result of a thorough collaboration between a
group of physiotherapists, a neurobiologist/-scientist and
their patients over years in clinical practice [47]. Given that
bodily dizziness and dysfunction is kind of a code that needs
to be understood as interactions between the body and the
brain, bodily expressions should attain more interest in the
future, both in clinical practice settings and in research.
Since LOP was conducted as part of the conventional
therapies within hospital settings, it is not clear from this
study whether results would have been the same if LOP was
offered in e.g. primary health care or other settings. The hos-
pital settings may at least theoretically influence patients’
confidence and thus results. The potential effects of treat-
ment settings should, therefore, be tested in future research.
For future use and further improvements in approach, it is
also important to get a deeper insight into the mechanisms
of LOP as a multifaceted therapeutic intervention (e.g. the
learning process, the focus on balance and the therapeutic
tools). Although RCT studies are considered the gold stand-
ard in effect studies, qualitative methods may contribute to
more in-depth knowledge about learning and recovering as
a process [59].
Strengths and limitations
The strength of the study is the study design, the use of reli-
able and validated measurements and the many repeated
assessments, as well the long term of follow-up. The study
was a pragmatic multicentre RCT, which largely is considered
as strength when assessing health service effectiveness. First,
it has the advantage of being an RCT, but secondly, the trial
was conducted as part of ordinary clinical practice, which
may make findings more applicable when it comes to inform
decisions about practice [31].
With the exception of the statisticians who did not know
which participants belonged to the different groups, it was
not possible to blind either the subjects or therapists. This,
of course, represents a weakness in such studies. Another
aspect that may have influenced results was that the LOP
therapists’ with great ownership of the method, might have
shown more interest and engagement than therapists/con-
sultants that treated patients in the control group. Such
influences cannot be controlled for, but may explain some of
the observed temporal differences in health outcomes
between the groups.
It is also likely that there has been some sort of selection of
patients since more than half of eligible patients declined the
invitation to participate. A majority of these preferred to receive
standard psychiatric treatment. Participants that were included
and followed in this study may, therefore, not be quite repre-
sentative for patients with moderate anxiety and depression as
such. Selection may, for example, explain why more women
than men participated, but due to the randomisation of
patients, possible selection of patients is not considered to bias
the comparisons between groups. It is not clear why a higher
proportion of participants in the LOP group compared to con-
trols had higher education, but the overall results were con-
trolled for education level and thus taken into account.
The results suggest that LOP is as effective as
‘psychotherapy’, but controls were given a range of different
therapies and we cannot know for sure if results were the same
if controls had received a more standardised psychotherapy. On
the other hand, these are probably fairly representative of the
therapies patients are offered at psychiatric clinics in Norway
and comparisons, therefore, considered to be adequate.
The drop-out rate in this study as for many RCT studies
represents a limitation, but was quite similar for both
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treatment arms. One should also keep in mind that the par-
ticipants were followed over 18 months with several data
assessments, i.e. conditions that increase the chance of drop-
ping out.
Conclusions
This study suggests that for patients with moderate anxiety
and depression, LOP may be a good alternative to more
traditional outpatient therapies.
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